Becton-Dickinson To Launch New Assay
Becton-Dickinson is to launch a new immune-function test for patients who are HIV-positive, called Fast-Immune, based on an early-activation marker code-named CD69. The test will become available for commercial research this month.
The assay is a quick, flow-cytometry-based measurement of T-cell activation levels in HIV-positive individuals. The new test has many advantages, according to the company; it uses whole blood at body temperature and takes only a few hours, compared to two weeks for earlier methods. The results should enable researchers to examine a patient's immune system response to HIV therapies in clinical trials, which can be used in predicting disease outcome.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze